“A consistent finding in all repeat-dose toxicity studies (up to 26 weeks in rats and up to 39 weeks in dogs) was dose-dependent reduction in cardiac contractility.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Why that species
Pharmacological activity: mavacamten is active (slightly more potent) in the toxicology species
“Mavacamten is slightly more potent in the species used for general toxicological assessment, and comparable potencies were exhibited by the recombinant wild type human beta cardiac myosin and five HCM mutants.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“A consistent finding in all repeat-dose toxicity studies (up to 26 weeks in rats and up to 39 weeks in dogs) was dose-dependent reduction in cardiac contractility.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗